Glycogen synthase kinase 3 regulates expression of nuclear factor-erythroid-2 related transcription factor-1 (Nrf1) and inhibits pro-survival function of Nrf1

Experimental Cell Research

Volumn 319, Issue 13, 2013, Pages 1922-1931

  Biswas, Madhurima ^a   Kwong, Erick K ^a   Park, Eujean ^a   Nagra, Parminder ^a   Chan, Jefferson Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CNC bZIP; Fbw7; Nuclear factor E2 related factor 1; Stress response; Transcription factor

Indexed keywords

ALANINE; GLYCOGEN SYNTHASE KINASE 3; SERINE; TRANSCRIPTION FACTOR NRF1;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

EID: 84879881580     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.04.013     Document Type: Article

References (41)

1. Andrews N.C., Erdjument-Bromage H., Davidson M.B., Tempst P., Orkin S.H. Erythroid transcription factor NF-E2 is a haematopoietic-specific basic-leucine zipper protein. Nature 1993, 362:722-728.
2. Chan J.Y., Han X.L., Kan Y.W. Cloning of Nrf1, an NF-E2-related transcription factor, by genetic selection in yeast. Proc. Natl. Acad. Sci. USA 1993, 90:11371-11375.
3. Kobayashi A., Ito E., Toki T., Kogame K., Takahashi S., Igarashi K., Hayashi N., Yamamoto M. Molecular cloning and functional characterization of a new Cap 'n' collar family transcription factor Nrf3. J. Biol. Chem. 1999, 274:6443-6452.
4. Moi P., Chan K., Asunis I., Cao A., Kan Y.W. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. USA 1994, 91:9926-9930.
5. Oyake T., Itoh K., Motohashi H., Hayashi N., Hoshino H., Nishizawa M., Yamamoto M., Igarashi K. Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol. Cell Biol. 1996, 16:6083-6095.
6. Chan J.Y., Cheung M.C., Moi P., Chan K., Kan Y.W. Chromosomal localization of the human NF-E2 family of bZIP transcription factors by fluorescence in situ hybridization. Hum. Genet. 1995, 95:265-269.
7. Motohashi H., O'Connor T., Katsuoka F., Engel J.D., Yamamoto M. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 2002, 294:1-12.
8. Chan J.Y., Kwong M., Lu R., Chang J., Wang B., Yen T.S., Kan Y.W. Targeted disruption of the ubiquitous CNC-bZIP transcription factor, Nrf-1, results in anemia and embryonic lethality in mice. EMBO J. 1998, 17:1779-1787.
9. Chen L., Kwong M., Lu R., Ginzinger D., Lee C., Leung L., Chan J.Y. Nrf1 is critical for redox balance and survival of liver cells during development. Mol. Cell Biol. 2003, 23:4673-4686.
10. Lee C.S., Lee C., Hu T., Nguyen J.M., Zhang J., Martin M.V., Vawter M.P., Huang E.J., Chan J.Y. Loss of nuclear factor E2-related factor-1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration. Proc. Natl. Acad. Sci. USA 2011, 108:8408-8413.
11. Xu Z., Chen L., Leung L., Yen T.S., Lee C., Chan J.Y. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc. Natl. Acad. Sci. USA 2005, 102:4120-4125.
12. Johnsen O., Murphy P., Prydz H., Kolsto A.B. Interaction of the CNC-bZIP factor TCF11/LCR-F1/Nrf1 with MafG: binding-site selection and regulation of transcription. Nucleic Acids Res. 1998, 26:512-520.
13. Kwong M., Kan Y.W., Chan J.Y. The CNC basic leucine zipper factor, Nrf1, is essential for cell survival in response to oxidative stress-inducing agents. Role for Nrf1 in gamma-gcs(l) and gss expression in mouse fibroblasts. J. Biol. Chem. 1999, 274:37491-37498.
14. Myhrstad M.C., Husberg C., Murphy P., Nordstrom O., Blomhoff R., Moskaug J.O., Kolsto A.B. TCF11/Nrf1 overexpression increases the intracellular glutathione level and can transactivate the gamma-glutamylcysteine synthetase (GCS) heavy subunit promoter. Biochim. Biophys. Acta 2001, 1517:212-219.
15. Ohtsuji M., Katsuoka F., Kobayashi A., Aburatani H., Hayes J.D., Yamamoto M. Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J. Biol. Chem. 2008, 283:33554-33562.
16. Radhakrishnan S.K., Lee C.S., Young P., Beskow A., Chan J.Y., Deshaies R.J. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol. Cell 2010, 38:17-28.
17. Venugopal R., Jaiswal A.K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. USA 1996, 93:14960-14965.
18. Wang W., Chan J.Y. Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal transmembrane domain Inhibition of nuclear translocation and transacting function. J. Biol. Chem. 2006, 281:19676-19687.
19. Wang W., Kwok A.M., Chan J.Y. The p65 isoform of Nrf1 is a dominant negative inhibitor of ARE-mediated transcription. J. Biol. Chem. 2007, 282:24670-24678.
20. Zhang Y., Crouch D.H., Yamamoto M., Hayes J.D. Negative regulation of the Nrf1 transcription factor by its N-terminal domain is independent of Keap1: Nrf1, but not Nrf2, is targeted to the endoplasmic reticulum. Biochem. J. 2006, 399:373-385.
21. Zhang Y., Lucocq J.M., Yamamoto M., Hayes J.D. The NHB1 (N-terminal homology box 1) sequence in transcription factor Nrf1 is required to anchor it to the endoplasmic reticulum and also to enable its asparagine-glycosylation. Biochem. J. 2007, 408:161-172.
22. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001, 2:769-776.
23. Frame S., Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 2001, 359:1-16.
24. Rayasam G.V., Tulasi V.K., Sodhi R., Davis J.A., Ray A. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 2009, 156:885-898.
25. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 2008, 8:83-93.
26. Biswas M., Phan D., Watanabe M., Chan J.Y. The Fbw7 tumor suppressor regulates nuclear factor E2-related factor 1 transcription factor turnover through proteasome-mediated proteolysis. J. Biol. Chem. 2011, 286:39282-39289.
27. Kim D., Dan H.C., Park S., Yang L., Liu Q., Kaneko S., Ning J., He L., Yang H., Sun M., Nicosia S.V., Cheng J.Q. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front. Biosci. 2005, 10:975-987.
28. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 1773, 2007:1263-1284.
29. Kaytor M.D., Orr H.T. The GSK3 beta signaling cascade and neurodegenerative disease. Curr. Opinions Neurobiol. 2002, 12:275-278.
30. Bijur G.N., Jope R.S. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J. Biol. Chem. 2001, 276:37436-37442.
31. Obeng E.A., Carlson L.M., Gutman D.M., Harrington W.J., Lee K.P., Boise L.H. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
32. Szokalska A., Makowski M., Nowis D., Wilczynski G.M., Kujawa M., Wojcik C., Mlynarczuk-Bialy I., Salwa P., Bil J., Janowska S., Agostinis P., Verfaillie T., Bugajski M., Gietka J., Issat T., Glodkowska E., Mrowka P., Stoklosa T., Hamblin M.R., Mroz P., Jakobisiak M., Golab J. Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. Cancer Res. 2009, 69:4235-4243.
33. Tsuchiya Y., Morita T., Kim M., Iemura S., Natsume T., Yamamoto M., Kobayashi A. Dual regulation of the transcriptional activity of Nrf1 by beta-TrCP- and Hrd1-dependent degradation mechanisms. Mol. Cell Biol. 2011, 31:4500-4512.
34. Steffen J., Seeger M., Koch A., Kruger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol. Cell 2010, 40:147-158.
35. Rada P., Rojo A.I., Chowdhry S., McMahon M., Hayes J.D., Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell Biol. 2011, 31:1121-1133.
36. Jiang T., Chen N., Zhao F., Wang X.J., Kong B., Zheng W., Zhang D.D. High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res. 2010, 70:5486-5496.
37. Shibata T., Ohta T., Tong K.I., Kokubu A., Odogawa R., Tsuta K., Asamura H., Yamamoto M., Hirohashi S. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. USA 2008, 105:13568-13573.
38. Ohta T., Iijima K., Miyamoto M., Nakahara I., Tanaka H., Ohtsuji M., Suzuki T., Kobayashi A., Yokota J., Sakiyama T., Shibata T., Yamamoto M., Hirohashi S. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008, 68:1303-1309.
39. Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V., Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006, 3:e420.
40. Galland F., Lacroix L., Saulnier P., Dessen P., Meduri G., Bernier M., Gaillard S., Guibourdenche J., Fournier T., Evain-Brion D., Bidart J.M., Chanson P. Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr. Relat. Cancer 2010, 17:361-371.
41. Vegran F., Boidot R., Coudert B., Fumoleau P., Arnould L., Garnier J., Causeret S., Fraise J., Dembele D., Lizard-Nacol S. Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma. Br. J. Cancer 2009, 101:1357-1364.